Imaging pulmonary NF-kappaB activation and therapeutic effects of MLN120B and TDZD-8

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Ansaldi, Dan ^a   Hod, Eldad A ^b   Stellari, Fabio ^c   Kim, Jae Beom ^a   Lim, Ed ^a   Roskey, Mark ^a   Francis, Kevin P ^a   Singh, Rajendra ^a   Zhang, Ning ^a  

^a Caliper Life Sciences   (United States)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^c CHIESI FARMACEUTICI S P A   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; LUCIFERASE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MLN 120B; TDZD 8; UNCLASSIFIED DRUG; 4 BENZYL 2 METHYL 1,2,4 THIADIAZOLIDINE 3,5 DIONE; 4-BENZYL-2-METHYL-1,2,4-THIADIAZOLIDINE-3,5-DIONE; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; I KAPPA B KINASE; IKBKB PROTEIN, MOUSE; THIADIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BIOLUMINESCENCE; C57BL 6 MOUSE; CANCER CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME KINETICS; ENZYME REGULATION; GENETIC TRANSFECTION; IMAGE ANALYSIS; IN VITRO STUDY; LONGITUDINAL STUDY; LUNG DISEASE; LUNG PARENCHYMA; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; SPECIES DIFFERENTIATION; TREATMENT RESPONSE; ANIMAL; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; LUNG; METABOLISM;

MUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; CHEMOKINE CCL4; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; I-KAPPA B KINASE; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; LUNG; MICE; NF-KAPPA B; THIADIAZOLES;

EID: 80053081588     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025093     Document Type: Article

References (42)

1. Kline JN, Cowden JD, Hunninghake GW, Schutte BC, Watt JL, et al. (1999) Variable airway responsiveness to inhaled lipopolysaccharide. Am J Respir Crit Care Med 160: 297-303.
2. Michel O, Kips J, Duchateau J, Vertongen F, Robert L, et al. (1996) Severity of asthma is related to endotoxin in house dust. Am J Respir Crit Care Med 154: 1641-1646.
3. Vernooy JH, Dentener MA, van Suylen RJ, Buurman WA, Wouters EF, (2001) Intratracheal instillation of lipopolysaccharide in mice induces apoptosis in bronchial epithelial cells: no role for tumor necrosis factor-alpha and infiltrating neutrophils. Am J Respir Cell Mol Biol 24: 569-576.
4. Vernooy JH, Dentener MA, van Suylen RJ, Buurman WA, Wouters EF, (2002) Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology. Am J Respir Cell Mol Biol 26: 152-9.
5. Ghosh S, May MJ, Kopp EB, (1998) NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16: 225-260.
6. Baeuerle PA, (1998) IκB-NF-κB structures: at the interface of inflammation control. Cell 11: 729-731.
7. Karin M, Delhase M, (2000) The IκB kinase (I 75 K) and NF-κB key elements of proinflammatory signalling. Semin Immunol 12: 85-98.
8. Tak PP, Firestein GS, (2001) NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107: 7-11.
9. Yao H, Rahman I, (2009) Current concepts on the role of inflammation in COPD and lung cancer. Curr Opin Pharmacol 9: 375-83.
10. Charokopos N, Apostolopoulos N, Kalapodi M, Leotsinidis M, Karamanos N, et al. (2009) Bronchial asthma, chronic obstructive pulmonary disease and NF-kappaB. Curr Med Chem 16: 867-83.
11. Frame S, Cohen P, Biondi RM, (2001) A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 7: 1321-1327.
12. Woodgett JR, (1990) Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9: 2431-2438.
13. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, et al. (1996) Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 272: 1023-1026.
14. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, et al. (2000) Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406: 86-90.
15. Ginger RS, Dalton EC, Ryves WJ, Fukuzawa M, Williams JG, et al. (2000) Glycogen synthase kinase-3 enhances nuclear export of a Dictyostelium STAT protein. EMBO J 19: 5483-5491.
16. Frame S, Cohen P, (2001) GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359: 1-16.
17. Van Wauwe J, Haefner B, (2003) Glycogen synthase kinase-3 as drug target: From wallflower to center of attention. Drug News Perspect 16: 557-565.
18. Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A, (2009) Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 156: 885-898.
19. Takada Y, Fang X, Jamaluddin MS, Boyd DD, Aggarwal BB, (2004) Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem 279: 39541-39554.
20. Carlsen H, Moskaug JØ, Fromm SH, Blomhoff R, (2002) In vivo imaging of NF-kappa B activity. J Immunol 168: 1441-6.
21. Zhang N, Weber A, Li B, Lyons R, Contag PR, et al. (2003) An Inducible Nitric Oxide Synthase-luciferase Reporter System for In Vivo Testing of Anti-inflammatory Compounds in Transgenic Mice. J Immunol 170: 6307-6319.
22. Hubbard AK, Timblin CR, Shukla A, Rincon M, Mossman BT, (2002) Activation of NF-kappaB-dependent gene expression by silica in lungs of luciferase reporter mice. Am J Physiol Lung Cell Mol Physiol 282: L968-L975.
23. Blackwell TS, Yull FE, Chen CL, Venkatakrishnan A, Blackwell TR, et al. (2000) Multiorgan nuclear factor kappa B activation in a transgenic mouse model of systemic inflammation. Am J Respir Crit Care Med 162: 1095-1101.
24. Yew NS, Scheule RK, (2005) Toxicity of cationic lipid-DNA complexes. Adv Genet 53: 189-214.
25. Densmore CL, (2006) Advances in noninvasive pulmonary gene therapy. Curr Drug Deliv 3: 55-63.
26. Mizuno T, Mohri K, Nasu S, Danjo K, Okamoto H, (2009) Dual imaging of pulmonary delivery and gene expression of dry powder inhalant by fluorescence and bioluminescence. J Control Release 134: 149-54.
27. Lesina E, Dames P, Rudolph C, (2010) The effect of CpG motifs on gene expression and clearance kinetics of aerosol administered polyethylenimine (PEI)-plasmid DNA complexes in the lung. J Control Release143: 243-50.
28. Nagashima K, Sasseville VG, Wen D, Bielecki A, Yang H, et al. (2006) Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKbeta. Blood 107: 4266-73.
29. Izmailova ES, Paz N, Alencar H, Chun M, Schopf L, et al. (2007) Use of molecular imaging to quantify response to IKK-2 inhibitor treatment in murine arthritis. Arthritis Rheum 56: 117-28.
30. Wang H, Brown J, Martin M, (2011) Glycogen synthase kinase 3: A point of convergence for the host inflammatory response. Cytokine 53: 130-40.
31. Schwabe RF, Brenner DA, (2002) Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes. Am J Physiol Gastrointest Liver Physiol 283: G204-G211.
32. Dugo L, Collin M, Allen DA, Patel NS, Bauer I, et al. (2005) GSK-3 beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit Care Med 33: 1903-1912.
33. Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A, (2009) Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 156: 885-898.
34. Cuzzocrea S, Crisafulli C, Mazzon E, Esposito E, Muià C, et al. (2006) Inhibition of glycogen synthase kinase-3beta attenuates the development of carrageenan-induced lung injury in mice. Br J Pharmacol 149: 687-702.
35. Cuzzocrea S, Mazzon E, Dugo L, Serraino I, Di Paola R, et al. (2002) Absence of endogenous interleukin-10 enhances the evolution of acute lung injury. Eur Cytokine Netw 13: 285-97.
36. Geraets L, Haegens A, Brauers K, Haydock JA, Vernooy JH, et al. (2009) Inhibition of LPS-induced pulmonary inflammation by specific flavonoids. Biochem Biophys Res Commun 382: 598-603.
37. Goodman RB, Strieter RM, Martin DP, Steinberg KP, Milberg JA, et al. (1996) Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med 154: 602-611.
38. Koay MA, Christman JW, Wudel LJ, Allos T, Cheng DS, et al. (2002) Modulation of endotoxin-induced NF-kappa B activation in lung and liver through TNF type 1 and IL-1 receptors. Am J Physiol Lung Cell Mol Physiol 283: L1247-54.
39. Hod EA, Zhang N, Sokol SA, Wojczyk BS, Ansaldi D, et al. (2010) Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron. Blood 115: 4284-92.
40. Worthen GS, Downey GP, (1996) Mechanisms of neutrophil mediated injury in ARDS Acute Respiratory Distress in Adults, In: Evans TW, Haslett C, editors. 99-114 Chapman and Hall.
41. Wang P, Wu P, Siegel MI, Egan RW, Billah MM, (1995) Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 270: 9558-63.
42. Bless NM, Huber-Lang M, Guo RF, Warner RL, et al. (2000) Role of CC chemokines (macrophage inflammatory protein-1 beta, monocyte chemoattractant protein-1, RANTES) in acute lung injury in rats. J Immunol 164: 2650-9.